StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →6-factor scoring with sector-relative rank. Updated daily.
Each row shows where CRL sits in our scored universe today on a single observational measurement. P85 means CRL ranks above 85% of peers on that factor right now. Percentile rankings are descriptive — they are not buy/sell signals or quality judgments. Universe refreshed every 60 seconds.
Today's volume vs prior session average.
Absolute daily price move vs peers.
24h article count relative to the universe.
AI-classified polarity of recent news.
Today's dollar turnover (volume × VWAP).
Signed daily return vs the rest of the universe.
Stonvex publishes percentile measurements as observational data only. Nothing here constitutes a recommendation, prediction, or advice about whether to buy, sell, or hold any security. Stonvex is not a registered investment advisor.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for CRL yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $163.91 | $159.12 | -2.92% | 0.8M |
| 05-15 | $157.54 | $150.85 | -4.25% | 1.4M |
| 05-18 | $152.20 | $149.93 | -1.49% | 1.6M |
| 05-19 | $150.59 | $152.43 | +1.22% | 1.1M |
| 05-20 | $152.81 | $156.03 | +2.11% | 0.9M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-28 | Annual 2025 2025-12-27 | Q3 2025 2025-09-27 | Q2 2025 2025-06-28 |
|---|---|---|---|---|
Revenue | $995.83M | $4.02B | $3.02B | $2.02B |
Operating Income | $119.90M | $25.16M | $308.60M | $174.80M |
Net Income | $-14.84M | $-144.34M | $132.22M | $77.80M |
EPS (Diluted) | $-0.30 | $-2.91 | $2.65 | $1.55 |
Total Assets | $7.73B | $7.14B | $7.51B | $7.56B |
Total Liabilities | $4.74B | $3.92B | $4.06B | $4.16B |
Cash & Equivalents | $191.83M | $213.77M | $207.10M | $182.82M |
Free Cash Flow OCF − CapEx | $-14.83M | $518.49M | $459.92M | $281.68M |
Shares Outstanding | 48.17M | 49.22M | 49.22M | 49.21M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.